Treatment of Multidrug-Resistant Tuberculosis in Indonesia

Abstract

There is growing concern, even among developed countries, about the increasing incidence of multidrug-resistant tuberculosis (MDR-TB). Results are reported from a study investigating ofloxacin used in the treatment of 57 patients with MDR-TB. Patients received ofloxacin 400 mg/day as well as three other sensitive anti-TB drugs based on susceptibility tests. Treatment duration was 9 months. Preliminary results of 35 evaluable patients show 55% of MDR-TB cases converted to smear and culture negative within 3 months of therapy. Ofloxacin in combination with other sensitive anti-TB medication shows promise in the treatment of MDR-TB and further studies are recommended.

Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran

“…In the study by Tahaoglu et al 22 the sputum culture was 1.9 (1-9) months. In the study by Hadiatro et al 13 from Indonesia, the sputum smear conversion rate was 50% over three months. The lack of effective second line drugs (e.g.…”

“…5 Many studies have investigated MDR-TB treatment worldwide. [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] Here, the first study on MDR-TB treatment in Iran is reported. It was carried out at Masih Daneshvari Hospital in Tehran between 2000-2002.…”

Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru

“…41 Therapy was more aggressive than in other studies; patients were treated with more drugs and at higher doses for longer periods. 13,41,43 It is likely that this protocol mitigated, to some degree, the effect of high-grade resistance. In other cohorts, such resistance has increased the likelihood of treatment failure.…”

“…It has been argued that drug-susceptibility testing and second-line drugs are not cost effective in these countries because of limited resources and that intensive clinical management is impossible because of lack of infrastructure. 3, 11,12 There are few treatment models, and the reported rates of success of treatment of multidrug-resistant tuberculosis in middle-income countries and regions ranged in recent reports from less than 60 percent in Indonesia and Taiwan 13,14 to just over 80 percent in Hong Kong, Korea, and Turkey. [15][16][17] In these studies, treatment of multidrug-resistant tuberculosis was costly and was provided in referral hospitals.…”

Review: Multidrug‐resistant tuberculosis: public health challenges

“…Reports on experience in treating MDRTB using second‐line drugs in middle‐income countries have been, until very recently, few in number, and from low‐income countries there have been none (Hadiarto et al. 1996; Suo et al.…”